GCGR
Glucagon receptor
As of the edition of 20 October 2026, GCGR (glucagon receptor, UniProt P47871) has 16 drugs tested at it and 18 companies on the list, 7 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P47871
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 29
- Disease areas
- Nutrition and metabolism; Hormones; Immune system; Digestive system; Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Nervous system
- Registered trials of its drugs
- 256
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 3 |
| Went quiet | 3 |
| Stopped | 6 |
| Total | 16 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Glucagon | Marketed | Phase 4 | none listed |
| Retatrutide | Active | Phase 3 | none listed |
| Survodutide | Active | Phase 3 | none listed |
| Dasiglucagon | Marketed | Phase 3 | none listed |
| Cotadutide | Stopped | Phase 2 | none listed |
| Adomeglivant | Stopped | Phase 2 | none listed |
| Efinopegdutide | Stopped | Phase 2 | none listed |
| Volagidemab | Active | Phase 2 | none listed |
| SAR425899 | Stopped | Phase 2 | none listed |
| MK-0893 | Went quiet | Phase 2 | none listed |
| PF-06291874 | Went quiet | Phase 2 | none listed |
| Glucagon hydrochloride | Marketed | Phase 3 | none listed |
12 of 16 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 3 |
| Engaged | 3 |
| Undetermined | 5 |
| Total on the list | 18 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| Pfizer | Route A |
| Merck & Co. | Route A |
The other 15 companies at GCGR
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at GCGR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.